Eiger BioPharmaceuticals Inc
EIGR
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.59M
Close$
$2.95
71.3% upside
Current Fair Value
71.3% upsideUndervalued by 71.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.59 Million |
|---|---|
| Enterprise Value | $28.35 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-50.78 |
| Beta | 1.85 |
| Outstanding Shares | 1,476,792 |
Return
| Return on Equity | 518.49% |
|---|---|
| Return on Assets | -193.07% |
| Return on Invested Capital | 489.45% |
Valuation & Multiples
| P/E Ratio | -0.17 |
|---|---|
| PEG | 0.36 |
| Price to Sales | 0.17 |
| Price to Book Ratio | -0.17 |
| Enterprise Value to Revenue | 1.8 |
| Enterprise Value to EBIT | -0.4 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.45 |
| Debt to Equity | -2.85 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eiger BioPharmaceuticals, Inc.
25 employees
CEO: Dr. David Apelian M.B.A., M.D., Ph.D. Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-...